Xcout IntelReplimune Group, Inc.
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.
Subscribe to see Replimune Group, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Replimune Group, Inc. at a glance
Replimune Group, Inc. is a biotech company headquartered in Woburn, United States. It is publicly listed (REPL) with a market capitalisation of $1.1B. Xcout tracks 20 named people at Replimune Group, Inc., including Sushil Patel (Chief Executive Officer & Director). Xcout recorded 94 job postings from Replimune Group, Inc. in the last 90 days, naming tools such as Jira, Oracle ERP, SAP.
Replimune Group, Inc. leadership
- Sushil PatelChief Executive Officer & Director
- Emily Luisa HillChief Financial Officer
- Konstantinos XynosChief Medical Officer
- Andrew SchwendenmanChief Accounting Officer & Treasurer
- Camilo GarciaChief Human Resource Officer
- Paul BullockChief Manufacturing Officer & Framingham Site Head
14 more named people on record for Replimune Group, Inc., with roles, board committees and tenure — see the full roster →
Hiring at Replimune Group, Inc.
Xcout recorded 94 job postings from Replimune Group, Inc. in the last 90 days, from a hiring record Xcout has kept since June 2026.
Tools named in Replimune Group, Inc.'s job postings
The weekly hiring trend, the roles and locations behind it — see Replimune Group, Inc.'s hiring signals →
Hiring vs the trend
Based on 52 job postings in the last 8 weeks (10 Aug – 4 Oct 2026), compared with 63 startup healthcare companies.
This describes a hiring pattern — how often Replimune Group, Inc.’s job postings ask for AI skills, and how that changed against the previous 8 weeks, ranked among its peers. It says nothing about the company’s products or performance.
Signed-in members see the AI-skill share and its change with peer percentiles, role mix, posting momentum and advertised US pay against the market.
Tech stack
Replimune Group, Inc. competitors
A few of Replimune Group, Inc.'s closest competitors — see the full list of competitors and alternatives →
Alloplex Biotherapeutics, Inc. is a privately owned clinical-stage cellular therapeutics company with headquarters and laboratories located in Woburn, Massachusetts, developing robust platforms for treating cancer.
Repertoire Immune Medicines is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts. The firm works to unlock and direct the power of the human immune system to develop novel therapeutics and medicines.
INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies. Its primary objective is to harness the body's innate immune system to combat various illnesses. The company is actively engaged in developing and bringing to market therapeutic candidates designed to address a spectrum of conditions such as blood cancers, solid tumors, and chronic inflammatory diseases. Its pipeline features key development programs including: INKmune: Aimed at treating women suffering from relapsed or refractory ovarian carcinoma and individuals diagnosed with high-risk myelodysplastic syndrome. INB03: An immunotherapy targeting patients with both hematologic malignancies and solid tumors. XPro1595: Under development for the treatment of Alzheimer's disease. INmune Bio holds licensing agreements with entities including Xencor, Inc., Immune Ventures, LLC, the University of Pittsburgh, and University College London. Established in 2015, INmune Bio is headquartered in Boca Raton, Florida.
Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on immuno-oncology, dedicated to developing advanced immunotherapies for various cancers. The company's innovative approach centers on utilizing powerful, allogeneic (donor-derived) stem cells as specialized carriers for anti-tumor agents. This technology is being advanced to address a range of oncological conditions, including aggressive brain tumors (high-grade gliomas) and other solid malignancies. Calidi's proprietary cell-based delivery systems are expertly designed to safeguard, amplify, and boost the therapeutic effects of oncolytic viruses. This strategic delivery method aims to achieve superior treatment efficacy and enhance patient safety. The company's clinical pipeline features two primary candidates: NeuroNova, which employs allogeneic neural stem cells loaded with an oncolytic adenovirus specifically for the treatment of high-grade gliomas; and SuperNova, which utilizes allogeneic adipose-derived mesenchymal stem cells to deliver the tumor-selective CAL1 oncolytic vaccinia virus for advanced metastatic solid tumors. Established in 2014, Calidi Biotherapeutics operates out of San Diego, California.
Checkmate Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on developing proprietary technology to stimulate the immune system to combat cancer.
Genprex, Inc. is a biotechnology firm specializing in gene therapy, with its primary focus on advancing treatments through clinical stages. Their mission revolves around developing innovative therapies for patients battling cancer and diabetes. Leading their product pipeline is REQORSA (GPX-001), a flagship gene therapy candidate specifically designed to target both non-small cell lung cancer and small cell lung cancer. In addition, Genprex is progressing GPX-002, another gene therapy at the preclinical stage, intended for the management of diabetes. The company was established in 2009 and operates from its corporate headquarters located in Austin, Texas.
Get Replimune Group, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Replimune Group, Inc. in Xcout Intel
- 20 named people with titles, LinkedIn and board committees
- Weekly hiring history and the mix of roles behind it
- 5 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access